Lab Domain Agenda 18October2011: Difference between revisions
Jump to navigation
Jump to search
Created page with "Back to ''' IHE Laboratory Domain''' Back to ''' IHE Laboratory Technical Committee Page''' ==Dial-In Information== * Date: ..." |
|||
| (6 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
==Dial-In Information== | ==Dial-In Information== | ||
* Date: Tuesday, October | * Date: Tuesday, October 18th | ||
* Time: 9:00-10:00 AM Eastern Time (USA, New York) | * Time: 9:00-10:00 AM Eastern Time (USA, New York) | ||
* Web Conference: [https://www1.gotomeeting.com/join/535282096 Join GoTo Meeting] | * Web Conference: [https://www1.gotomeeting.com/join/535282096 Join GoTo Meeting] | ||
| Line 16: | Line 16: | ||
==Agenda== | ==Agenda== | ||
: | # F2F Meeting Follow-up Tasks (from Minutes) | ||
# LBL Supplement (progress report) | |||
#* [ftp://ftp.ihe.net/Laboratory/ihelabyr-2011-2012/Profile_Work/LBL/IHE_LBL_Supplement_Sulis_Frexia.doc LBL Supplement Draft] | |||
# LAW Supplement (progress report) | |||
# CP 171 Discussion | |||
# Strategic Planning (due Nov 21) | |||
#* 3-5 yr roadmap | |||
#* designation of a cross-domain liason | |||
Latest revision as of 10:04, 12 October 2011
Back to IHE Laboratory Domain
Back to IHE Laboratory Technical Committee Page
Dial-In Information
- Date: Tuesday, October 18th
- Time: 9:00-10:00 AM Eastern Time (USA, New York)
- Web Conference: Join GoTo Meeting
- Audio Conference
You will be connected to audio using your computer's microphone and speakers (VoIP). A headset is recommended. Or, you may select "Use Telephone" after joining the Webinar.
- Dial: United States: +1 (215) 383-1010 or France: +33 (0) 182 880 458 or United Kingdom: +44 (0) 121 368 0267
- Access Code: 535-282-096
- Audio PIN: Shown after joining the meeting
- Meeting ID: 535-282-096
Agenda
- F2F Meeting Follow-up Tasks (from Minutes)
- LBL Supplement (progress report)
- LAW Supplement (progress report)
- CP 171 Discussion
- Strategic Planning (due Nov 21)
- 3-5 yr roadmap
- designation of a cross-domain liason